Diversity Plans To Improve Enrollment Of Participants From Underrepresented Racial & Ethnic Populations In Clinical Trials Guidance For Industry

In April 2022, the U.S. Food and Drug Administration published a guidance to provide recommendations to sponsors developing medical products on the approach for developing a Race and Ethnicity Diversity Plan to enroll representative numbers of participants from underrepresented racial and ethnic populations in the United States . . .